We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

News   Aug 01, 2018 | Original story from the National Institute of Standards and Technology (NIST)

 
New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

HeLa cancer cells appear green wherever mouse monoclonal antibodies (mAb) have bound to tubulin, a structural protein important in cell division. Binding to tubulin and preventing cell growth is one way that mAb drugs could kill tumors—the type of research that may benefit from the use of NIST's monoclonal antibody reference material, NISTmAb. Credit: ©EnCor Biotechnology Inc.

 
 
 

RELATED ARTICLES

Mouse Model Shows Gene Therapy Vectors Carrying Telomerase Gene Do Not Increase Cancer Risk

News

Gene therapy with telomerase was developed in 2012 and has proved effective in mice against infarction, as well as in mouse models of aplastic anaemia and idiopathic pulmonary fibrosis associated to short telomeres.

READ MORE

Antibiotic Candidates Discovered

News

MIT researchers have discovered that peptides normally secreted by cells that line the stomach have previously unknown antimicrobial activity.

READ MORE

Zika Vaccine Clinical Trial Begins

News

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE